• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tevogen Bio Holdings Inc. - Warrant (NQ:TVGNW)

    0.0506 UNCHANGED
    Streaming Delayed Price Updated: 3:50 PM EDT, Oct 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Tevogen Bio Holdings Inc. - Warrant

    < Previous 1 2 3 4 5 Next >
    Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
    From Tevogen Bio Inc
    Via GlobeNewswire
    REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
    From Tevogen Bio Inc
    Via GlobeNewswire
    Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
    From Tevogen Bio Inc
    Via GlobeNewswire
    REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
    From Tevogen Bio Inc
    Via GlobeNewswire
    REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
    From Tevogen Bio Inc
    Via GlobeNewswire
    REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
    From Tevogen Bio Inc
    Via GlobeNewswire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.